Lv31
220 积分 2025-08-27 加入
Real‐World Efficacy and Safety of Abrocitinib in Chinese Atopic Dermatitis Patients: A Single‐Center Prospective Study
2小时前
待确认
Disease modification in inflammatory skin disorders: opportunities and challenges
2天前
已完结
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial
2天前
已完结
Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations
2天前
已完结
Treatment-resistant atopic dermatitis: novel therapeutics, digital tools, and precision medicine
4天前
已关闭
Factors Associated with Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-analysis
4天前
已完结
Discontinuation Reasons and Drug Survival of Dupilumab in Real‐World Adult Atopic Dermatitis Patients in Three Healthcare Facilities in Tokyo and Yokohama (2018–2023)
4天前
已完结
Addressing Unmet Needs in Atopic Dermatitis: Evaluating Disease-Modifying Capabilities of Current and Emerging Therapies
4天前
已完结
Adjunctive Management of Itch in Atopic Dermatitis
15天前
已完结
Atopic Dermatitis beyond Eczema: A Review on its Systemic Impact through Pruritus and Associated Comorbidities
15天前
已完结
[Para-Bombay phenotype due to bi-allelic heterozygous base deletions of FUT1 gene]
皖公网安备34019202002308
